PE firm Warburg Pincus has announced it will invest up to $300 million in new pharmaceutical company Vertice Pharma.

Vertice Pharma, which has its U.S. headquarters in New Jersey, will focus on acquiring specialty pharmaceutical companies and products. It was launched by pharmaceutical industry veterans Don DeGolyer and Andrew Saik in partnership with Warburg Pincus.

Vertice Parma’s first acquisition is VistaPharm, a Birmingham, Ala.-based specialized generics manufacturer of liquid and unit dosage pain medications for the hospital market, retail pharmacy and outpatient clinics.

Warburg Pincus, headquartered in New York, was founded in 1966. The firm focuses primarily on investing in healthcare and consumer products; technology, media and telecommunications; financial services; energy; and industrial and business services. It has invested more than $50 billion in more than 720 companies located in more than 35 countries.